Kyverna Therapeutics Past Earnings Performance
Past criteria checks 0/6
Kyverna Therapeutics's earnings have been declining at an average annual rate of -49.4%, while the Biotechs industry saw earnings growing at 17.5% annually.
Key information
-49.44%
Earnings growth rate
73.43%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | n/a |
| Return on equity | -64.92% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
No updates
Recent updates
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Mar 21Kyverna Therapeutics: CAR T-Cells Trying To Impact Inflammatory Disorders
Dec 12Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation
Nov 17
We're Not Very Worried About Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate
Aug 08Revenue & Expenses Breakdown
How Kyverna Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 0 | -145 | 34 | 0 |
| 31 Dec 24 | 0 | -127 | 30 | 0 |
| 30 Sep 24 | 0 | -111 | 24 | 0 |
| 31 Mar 24 | 0 | -76 | 16 | 0 |
| 31 Dec 23 | 0 | -60 | 12 | 0 |
| 30 Sep 23 | 0 | -48 | 10 | 0 |
| 31 Dec 22 | 7 | -29 | 8 | 0 |
| 31 Dec 21 | 6 | -26 | 6 | 0 |
Quality Earnings: KYTX is currently unprofitable.
Growing Profit Margin: KYTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KYTX is unprofitable, and losses have increased over the past 5 years at a rate of 49.4% per year.
Accelerating Growth: Unable to compare KYTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KYTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: KYTX has a negative Return on Equity (-64.92%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 07:43 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kyverna Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Lut Ming Cheng | J.P. Morgan |
| Thomas Smith | Leerink Partners LLC |